Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2024 1
2025 60
2026 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Oshima MU, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly LS, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Mendizabal A, Devine SM, Horowitz MM, Chen YB. Levis MJ, et al. Blood. 2025 May 8;145(19):2138-2148. doi: 10.1182/blood.2024025154. Blood. 2025. PMID: 39775763 Free article. Clinical Trial.
FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells.
Araújo JL, Wagenblast E, Voisin V, McLeod J, Gan OI, Bansal S, Jin L, Mitchell A, Gratton B, Cutting S, Arruda A, Doedens M, Travas A, Kim D, Capo-Chichi JM, Abelson S, Minden MD, Wang JCY, Sobrinho-Simões MA, Pinto-do-Ó P, Lechman E, Dick JE. Araújo JL, et al. Blood. 2025 May 15;145(20):2361-2373. doi: 10.1182/blood.2024025886. Blood. 2025. PMID: 39841016 Free PMC article.
Mutant IDH1 cooperates with NPM1c or FLT3(ITD) to drive distinct myeloid diseases and molecular outcomes.
Sakamoto T, Leca J, Zhang X, Meydan C, Foox J, Ramachandran P, Hendrikse LD, Zhou W, Berger T, Fortin J, Chan SM, Chiang MF, Inoue S, Li WY, Chu MF, Duncan GS, Wakeham A, Lemonnier F, Tobin C, Mcwilliam R, Colonna I, Bontoux C, Jafari SM, Bowman RL, Nicolay B, Ronseaux S, Narayanaswamy R, Levine RL, Melnick AM, Mason CE, Minden MD, Mak TW. Sakamoto T, et al. Proc Natl Acad Sci U S A. 2025 May 20;122(20):e2415779122. doi: 10.1073/pnas.2415779122. Epub 2025 May 16. Proc Natl Acad Sci U S A. 2025. PMID: 40377995 Free PMC article.
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Oshima MU, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly LS, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson K, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal A, Devine SM, Horowitz MM, Chen YB. Levis MJ, et al. Blood Adv. 2025 Oct 28;9(20):5123-5133. doi: 10.1182/bloodadvances.2025016306. Blood Adv. 2025. PMID: 40590852 Free PMC article. Clinical Trial.
Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.
Montesinos P, Rodríguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodríguez-Arbolí E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, López-López JA, Vives S, López-Lorenzo JL, Colorado M, Vidriales MB, García Boyero R, Olave MT, Herrera Puente P, Arce O, Barrios M, Jose Sayas M, Polo M, Gómez-Roncero MI, Barragán E, Ayala R, Chillón C, Calasanz MJ, Paiva B, Boluda B, Casas-Avilés I, Lloret-Madrid P, Sánchez MJ, Rodríguez-Medina C, Cuevas L, Raposo-Puglia JÁ, Mateos MC, Olivares M, Martínez-Chamorro C, Alonso N, Suárez S, Sánchez-Vadillo I, Solé Rodríguez M, González BJ, Martínez-Francés A, Cuello R, Fernández A, Martínez-Cuadrón D, Labrador J; PETHEMA group; PETHEMA Group. Montesinos P, et al. J Clin Oncol. 2026 Jan;44(1):42-53. doi: 10.1200/JCO-25-01841. Epub 2025 Oct 13. J Clin Oncol. 2026. PMID: 41082703 Free PMC article. Clinical Trial.
FLT3-ITD measurable residual disease from the QuANTUM-First trial.
Levis MJ, Erba HP, Montesinos P, Kim HJ, Vrhovac R, Patkowska E, Žák P, Wang PN, Connolly Rohrbach JE, Chang KCN, Liu L, Mostafa Kamel Y, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Schlenk RF, Perl AE. Levis MJ, et al. Blood Adv. 2026 Feb 10;10(3):917-928. doi: 10.1182/bloodadvances.2025016444. Blood Adv. 2026. PMID: 41052406 Free PMC article. Clinical Trial.
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.
Russell N, Othman J, Cumming O, Thomas A, Tedjaseputra A, Potter N, Jovanovic J, Gilkes A, Batten L, Canham J, Hinson E, Runglall M, Aucken P, Kottaridis P, Cavenagh J, Arnold C, Freeman S, Dennis M, Knapper S, Dillon R. Russell N, et al. Blood Adv. 2025 Dec 23;9(24):6455-6466. doi: 10.1182/bloodadvances.2025017244. Blood Adv. 2025. PMID: 41026969 Free PMC article. Clinical Trial.
FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia.
Zwick M, Zinkel B, Spohr C, Rückert T, Halbach S, Shoumariyeh K, Scheid J, Baur AS, Braun LM, Angel M, Michaeli E, Todkar A, Nelde A, Märklin M, Holzmayer SJ, Dicks S, Boerries M, Duquesne S, Schlaak AE, Otto-Mora P, Bengsch B, Schiff M, Kissel S, Selle M, Follo M, Altmann H, Kunadt D, Illert AL, Walz JS, Walz G, Duyster J, Schetelig J, Brummer T, Zeiser R, Köhler N. Zwick M, et al. Cancer Res. 2026 Jan 16;86(2):367-386. doi: 10.1158/0008-5472.CAN-25-0349. Cancer Res. 2026. PMID: 41043134
72 results